Givinostat is expected to exert a clinically relevant therapeutic effect on polyarticular JIA through the inhibition of the production/release of pro-inflammatory cytokines, such as IL-1β, IL-6 and TNFα, which are involved in the pathogenesis of the arthritic process.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01557452?cond=%22Arthritis%22&lup_s=01/29/2014&lup_d=30
